Chronic myelomonocytic leukemia (CMML) shares with other myeloid diseases a number of somatic gene mutations. These mutations can now be integrated within the framework of evolution theory to address the mechanisms of the disease. Several evidences indicate that the disease emerges in adult hematopoietic stem cells (HSC) through the age-dependent accumulation of DNA damage, leading stochastically to a driver mutation that confers a competitive advantage to the cell. A mutation in TET2 gene could be one of these driver mutations provoking the emergence of clonality. After a long latency, secondary lesions, such as mutations in the SRSF2 gene, contribute to progression to full-blown malignancy, with abnormal differentiation. Additional mutations accumulate and branching arising mostly through mitotic recombination generates clonal heterogeneity. Modifications in the microenvironment probably affect this clonal dynamics, whereas epigenetic alterations, such as hypermethylation of the TIF1g gene promoter, may generate phenotypic diversification of otherwise clonal populations. The preserved although deregulated myeloid differentiation that characterizes CMML, with granulomonocyte expansion and various cytopenias, may depend on early clonal dominance in the hematopietic cell hierarchy. Progression to acute myeloid leukemia observed in 25-30% of the patients may arise from the massive expansion of a clone with novel genetic lesions, providing a high fitness to previously minor subclones when in chronic phase of the disease. This review discusses the various models of disease emergence and progression and how this recent knowledge could drive rational therapeutic strategies.
INTRODUCTION
The WHO classification of myeloid malignancies describes chronic myelomonocytic leukemia (CMML) as the most frequent myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). 1 As MPN and MDS, this disease is characterized by a clonal (or sometimes oligoclonal) hematopoiesis with abnormal myeloid differentiation. In CMML, myeloid differentiation is either dysplastic, leading to cytopenias, or exaggerated, leading to myeloproliferation, or both. All these myeloid neoplasms share a variable risk of transformation to acute myeloid leukemia (AML). They also share somatic gene mutations that target the epigenetic control of transcription, such as histone modification (ASXL1, EZH2, UTX), DNA methylation (TET2, DNTM3A), or both (IDH1, IDH2), and the cohesin complex components STAG2, SMC3, SMC1A and RAD21), cytokine signaling (JAK2, MPL, LNK, CBL, RAS and genes of the Notch2 pathway) and pre-mRNA splicing (SRSF2, SF3B1, U2AF1, ZRSR2). These mutations and the current understanding of their molecular consequences have been extensively reviewed in the recent years. [2] [3] [4] [5] [6] There prevalence, phenotypic association and prognostic significance are summarized in Table 1 .
Starting with Peter Nowell, 7 cancer has long been envisioned as an evolutionary, Darwinian process driven by the sequential acquisition of genetic lesions followed by clonal expansion and selection. 8 The advent of high throughput genetic analyses, 9 single-cell assays, 10 and xenotransplantation assays, 11 has revealed the genetic heterogeneity of some myeloid neoplasms, with frequent oligoclonality, 12, 13 and the functional heterogeneity of leukemic cells, including those defined as leukemia-initiating cells (LIC). 14, 15 These new findings that reconcile genetic, immunophenotypic and functional observations, now require integration with the concepts of evolution theory. 16, 17 In CMML, the first results of whole-exome sequencing indicate that the number of non-synonymous mutations in coding regions varies between 5 and 20 per patient, 12, 18, 19 (Merlevede et al., unpublished results). Cytogenetic abnormalities have been found in 30%, 20 and copy-neutral acquired uniparental disomies in 50%, 21 of cases. Yet, the precise extent of non-exonic genetic, 13 as well as epigenetic [22] [23] [24] abnormalities remains unknown. In the present review, we integrate recent findings on the biology of CMML within the conceptual framework of evolution theory to address the mechanisms of disease initiation, progression, phenotype specification and transformation, and discuss how these recent insights could support the design of rational therapeutic strategies.
HEMATOPOIETIC STEM CELLS (HSC) AS CELLS-OF-ORIGIN AND LIC FOR CMML
There are two main evidences that adult HSC are the normal cells, in which initial genetic lesions have arisen in CMML. First, gene mutations are present in sorted HSC, as defined by their CD34 þ / CD38 À /CD90 þ phenotype. 25 Similar findings have been made with chromosomal lesions in MDS, 26 and with JAK2 and TET2 mutations in MPN. 27 Though the limited SCID-repopulating activity of CMML has hampered the functional validation of these phenotypically-defined HSC, 28 they contain most of the serial replating potential of CD34 þ cells in vitro. 25 Second, a fraction of T cells belongs to the leukemic clone, which thus has lympho-myeloid potential. Again, a similar observation was made in MPN, in which mutations in JAK2 29 and in TET2 30 were identified also in some lymphoid cells. This suggests that a normal self-renewal hierarchy, with HSC serving as LIC, is maintained in CMML hematopoiesis, which is different from de novo 31 or secondary 32 AML, in which progenitors are candidate LIC. Though this notion needs strengthening in CMML, it raises issues regarding the contribution of HSC niches, 33 compartmental heterogeneity 34 and physiological aging, 35 to the emergence of the disease.
INITIATION OF CMML: EARLY GENETIC LESIONS
Accumulation of DNA damage depends on cell replication and metabolic activity and is therefore limited in quiescent and hypoxic HSC. 36 DNA damage that nevertheless occurs in a HSC can trigger the p53 37, 38 and p16 39 checkpoints required for the maintenance of self-renewal as well as survival. If DNA damage accumulates, HSC are either driven to exhaustion through increased differentiation, 37 or outcompeted by other HSC because of impaired self-renewal. 40 It is unlikely that a defect in those checkpoints has a role in CMML initiation as mutations in TP53 and related genes are very infrequent, 25 somatic mutations in other key checkpoint and DNA repair genes have not been reported, and progression to CMML has not been observed in patients with congenital DNA repair defects.
Therefore, early genetic lesions may be generated by DNA damage accumulating in aging HSC 41 despite functional repair and checkpoints machineries. Critical telomere attrition markers have not been detected in CMML, 42 in which the single nucleotide variant pattern is dominated by transitions (Merlevede et al., unpublished results), as in MDS, 12, 18, 19 and in AML. 13 Normal HSCs accumulate these transitions with age through replication errors, deamination of methylcytosines and oxidative damage. 13 Insertions/deletions generating CMML may be fueled by defaults in non-homologous end joining, the only mechanism available to quiescent cells to repair double strand breaks. 38 Most of the mutations that arise randomly in HSC may not affect HSC self-renewal and differentiation potential, thus are likely to be 'passengers'. Though mutations may not always occur independently, 43 and private mutations may not necessarily be 'passengers', they can be used as probes or 'molecular clocks' to measure the mutational rate in HSC, which has been estimated to be 0.1 mutation per HSC and per year. 13 Such a rate is in keeping with both the number of single nucleotide variant in CMML and other myeloid neoplasms, and the estimated number and division rate of normal human HSC, 44 further indicating that stochastic consequences of aging, rather than genetic instability, may be at the origin of these diseases.
CMML INITIATION: EMERGENCE OF CLONALITY
At some point, a lesion conferring a competitive advantage to the HSC can occur. Such 'competitive advantage' is best expressed in terms of 'fitness', a concept brought from evolution theory to the cancer field 8, 16 and measuring the proliferation rate of a homogeneous population compared with that of a reference population. The fitness of a preleukemic or leukemic clone is relative to that of other clones and of residual normal HSC. Fitness is also context-dependent, for example, is affected by changes in the microenvironment or by therapy. The fitness variations of a given clone are referred to as the 'fitness landscape' of the clone.
In most cancers, driver mutations are defined based on interpatient recurrence and predicted functional relevance. In myeloid malignancies, the availability of competitive transplantation assays in mice provides an opportunity to estimate fitness experimentally. Driver mutations may be those that confer a selective advantage to the tumor cell (that is, fitness 41) as opposed to passenger mutations, which are neutral or slightly detrimental.
In addition to the fitness landscape of the mutations, the kinetics of clonal expansion is influenced by the size of the target cell population and the mutation rate ( Figure 1) . 16 Current mathematical models of chronic myeloid neoplasms assume that preleukemic clones compete with normal HSC for the same niches, with a constant number of stem cells. 45 The recent finding of such a 'competition' process, neutral in terms of HSC pool size, during normal hematopoiesis, 40 and the direct visualization of leukemic cells competing with normal HSC for the same niches, 46 supports this model. Though this hypothesis may apply to CMML, where the proportion of phenotypic HSC is similar to age-matched controls, 25 it warrants careful experimental validation. Several lines of evidence suggest that mutations in TET2 are initial driver lesions in some CMML. These include the high frequency of these mutations, which can be detected in up to 60% of CMML patients, 30, 47, 48 the competitive advantage of murine and human HSC invalidated for TET2, [49] [50] [51] and the results of single-cell clonal tracking experiments indicating that a TET2 mutation, when present, is often the earliest recurrent genetic event in CMML, 25 as well as in MPN 52 and in AML. 53 Finally, TET2-mutated clones can be detected in a small fraction of older subjects with clonal, but non-leukemic, hematopoiesis. 54 Actually, SNP arrays can detect in a significant proportion of healthy subjects (0.8%) a somatic mosaicism (50% acquired uniparental disomies, 35% deletion, 15% gain) that may predispose to a broad spectrum of hematological malignancies, including chronic myeloid neoplasms. 55 These observations suggest a two-step model, where initial lesions, such as mutations in TET2, drive the emergence of clonality, and secondary lesions contribute to progression to fullblown malignancy, with abnormal differentiation. In exceptional cases, the initial event may be germinal, for example, germline RUNX1 mutations were reported to evolve to CMML by acquiring CBL mutations. 56 Other gene mutations, such as the frequent mutations in the ASXL1 gene (B40% of cases), could also trigger CMML. Mechanisms of ASXL1-induced leukemogenesis could involve the increased expression of HOXA genes, which are critical regulators of HSC self-renewal. 57 Mathematical models predict a long latency in chronic myeloid neoplasms. 45 If the high fitness value of initial driver mutations could account for the rapid onset of clonality and clinical manifestations in AML, 13 the long latency observed in CMML and other chronic myeloid neoplasms could be due to the small fitness advantage of TET2 and other initial driver mutations in these diseases, that is, these mutations may not deregulate HSC proliferation. Such a limited competitive advantage (fitness as low as 0.4%) has been described for bona fide oncogenic mutations involved in solid tumors, leading to long times (410 years) to fixation. 58 Mutations with a small fitness value may not always reach fixation and could disappear spontaneously, a phenomenon that has been exceptionally noted after diagnosis but could occur at the preclinical stage. 59 Of note, these observations raise concerns regarding the above-mentioned capability of competitive repopulation assays to discriminate driver from passenger mutations.
SPOTLIGHT
The long latency between the initial driver mutation appearance and disease expression could explain why TET2 mutations are not found in pediatric myeloid neoplasms, including juvenile myelomonocytic leukemias (JMML). 60 Another explanation is provided by the 'adaptive oncogenesis' model, 35 which postulates that some mutations may prove advantageous only when competing against normal cells functionally impaired by aging. It remains undetermined whether TET2 mutations confer an advantage to HSC when competing with older but not younger normal HSC, but this model could account for the rapid accumulation of copynumber alterations after the age of 50 in healthy subjects. 55 The heterogeneous clonal burden of TET2 mutations in CD34 þ cells, depending on the chronic myeloid neoplasm, is another parameter that could affect disease progression. TET2 mutations are present in the majority of HSC in CMML 25 and primary myelofibrosis 61 and in a minority of HSC in essential thrombocytemia, polycythemia vera 52 and possibly MDS. 25 These differences may reflect (1) the stochasticity of clonal expansion, 62 (2) the heterogeneity of normal HSC self-renewal potential, 34 (3) a 'density dependence' phenomenon observed when the mutated clone behaves as a 'social cheater' relying on non-mutant cells for resources, 63 for example, a mutation that would confer a selfrenewal advantage but enhance the cell dependence on paracrine signaling ( Figure 2 ). Finally, one of the likeliest explanations for these differences in clonal expansion trajectories could be the role of additional mutations.
PROGRESSION TO CMML: THE ROLE OF ADDITIONAL MUTATIONS
The finding that TET2 and ASXL1 mutations both confer selective advantages as single lesions, and that their association in CMML is less frequent than expected by chance 25 comforts the notion that these two lesions are independent drivers of CMML. Then, the two-step 'linear' model proposed earlier suggests that a combination of mutations is required for the progression from clonal hematopoieisis to CMML (Figure 3) . The occurrence of a secondary mutation could be favored by the higher mutation rate observed following the initial mutation, suggesting genetic instability, for example, JAK2 mutations activate DNA damage checkpoints 64 and NRAS mutations promote oxidative damage. 65 In another scenario called epistasis, a neutral or even slightly detrimental mutation hitchhikes on the initial driver lesion, then becomes advantageous. 66 One example is the cooperation of Ras and Myc oncogenes in the mouse. The specific prognostic impact of gene mutations combinations in AML 67 and in MDS, 68 argues for a role of epistasis in myeloid malignancies.
In CMML, an epistatic relation could exist between SRSF2 and TET2 mutations. A mutation in at least one splice gene is observed in more than 60% of CMML and, in most cases, mutations in diverse splice genes are mutually exclusive. 25 In CMML and in MDS, mutations in the splice gene SRSF2 are frequently combined with mutations in TET2. 25, 47, 68 In normal hematopoietic cells, splice-gene mutations induce a proliferation defect in vitro and a competitive disadvantage in vivo. 18 A TET2/SRSF2 synthetic viability, with SRSF2 mutation being neutral or detrimental in a TET2-wild-type, and becoming advantageous in a TET2-mutated cell, could explain why the mutational order is biased, 66 with TET2 mutations often preceding SRSF2 mutations. 25 An epistatic relation could also exist between mutations in signaling genes (CBL, NRAS, KRAS and JAK2) and other genetic lesions, especially TET2 mutations, in CMML. 25 In some situations, isolated JAK2 mutations may be detrimental to HSC. Similarly, although they may confer a small, but significant competitive advantage to murine HSC, 69 KRAS and NRAS mutations may also trigger oncogenic senescence, which would be bypassed by additional mutations, for example, in RUNX1 70 or ASXL1.
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CLONAL HETEROGENEITY AND ARCHITECTURE
In contrast with Peter Nowell's model, 7 in which each additional mutation induced a selective sweep removing its ancestor Residual HSC Driver mutation Figure 1 . Determinants of fitness of a leukemic clone: The emergence and clonal expansion of a preleukemic or leukemic clone, generated by a driver mutation in a target cell, for example, a HSC, is determined by the fitness of this first mutation (red dot), the mutation rate, the size of the target cell population (in shaded gray, w/o shown nucleus), the influence of passenger mutations (green and yellow dots), the competition with residual normal cells, and with distinct sublones, the microenvironment (cells shown with a nucleus) and therapy.
clone, the genetic heterogeneity within tumors is now extensively recognized. 8, 16, 17 This heterogeneity can be explored by different methods with variable sensitivity 71, 72 (see also the legend of Figure 5 ).
In most CMML cases (Figure 4 ), the clone architecture is mostly linear, as in de novo MDS 12 and in AML. 13, 53 Split architecture with several branching arising from the same ancestor can however, be observed, resulting mostly from LOH at mutated loci, for example, at the TET2 or at the CBL loci, 25 and possibly at many other loci without any fitness advantage. LOH was also described in ALL where it is due to illegitimate recombination. 14 In CMML, LOH mostly involves mitotic recombination, 25 generating two daughter cells, one homozygous for the mutation, the other one reverting to wild-type status. Mutations in JAK2, RAS 65 and members of the cohesin complex 13 could promote mitotic recombination, together with increased HSC proliferation.
Lastly, 'clonal interference' is an infrequent process leading to clonal branching that occurs when two driver lesions with similar fitness arise independently. 73 We have observed such a case with a competition between an NRAS and a KRAS-mutated clone, but failed to identify any mosaicism of concomitant splice-gene mutations. could have a relatively low fitness value compared with early driver lesions. However, this explanation does not fit with their short fixation time compared with initial lesions. 58 Second, each new oncogenic lesion could further perturb cellular signaling and transcription networks, which exhibit limited flexibility. 74 As mutations accumulate, the 'network compatibility' of additional lesions may narrow until the dominant clone faces an evolutionary bottleneck. 67 The accumulation of numerous so-called 'passenger' mutations could generate a molecular 'noise' leading to phenotypic alterations, 74 (for example, the accumulation of altered proteins may trigger a heat-shock protein response), but these noise-driven phenotypic transitions could remain under tight control in multicellular organisms. 75 Third, a cooperative 'commensalism' could exist between subclones, through paracrine signaling, 76 or direct cell-cell interactions. 77 Last, minor subclones could demonstrate increased adaptability in the context of a changing environment, for example, hypoxia or therapeutic challenge. 78 Leukemias with a minor fraction of LIC spontaneously accumulate a high degree of genetic heterogeneity, with some minor subclones having reduced fitness, probably because the infrequent replication of LIC alleviates selection pressures. This last model explains how genetic and functional heterogeneities are both robustly maintained during oncogenesis, each mechanism reinforcing the other.
NICHE CONTRIBUTIONS
Normal HSCs are tightly regulated by microenvironmental cues, including cell-cell interactions, soluble molecules and anatomical and physical constraints in the so-called HSC niche. HSC may traffic between an endosteal, presumably hypoxic niche, where they interact with immature osteoblasts, and a perivascular, possibly normoxic niche. The limited ability to xenotransplant CMML in immunodeficient mice could indicate a role for the microenvironment in sustaining leukemogenesis. 28 In silico modeling suggests that increasing the frequency, at which HSC traffic between different niches can promote tumor growth 79 and favor the coexistence of competing subclones with different requirements. Leukemic cells can induce microenvironmental changes impairing the functionality of residual normal HSC. 46 Conversely, gene deletion targeted to a microenvironmental cell type in the mouse could lead to MDS, 33 or to MPN. 80 Evolution theory predicts three ways, in which microenvironment modifications could affect clonal dynamics. First, altered niches could reduce the size of the HSC pool, thereby promoting the fixation of neutral mutations. However, bone marrow failure syndromes do not progress to CMML. Second, altered niches could contribute to genetic instability of HSC by modulating oxygen tension, and promoting oxidative DNA damage such as 8-oxoguanines. Finally, alterations in environmental cues could modulate the fitness landscapes of mutations; in particular microenvironment aging promotes benign and preleukemic clones. 81 This combination of mechanisms may be at work when disease initiation is triggered by chronic inflammation, 82 which induces oxidative damage and triggers HSC proliferation. 83 Older HSC are particularly sensitive to global elevation in levels of reactive oxygen species. 84 Inflammatory cytokines like TNFa could also modulate fitness landscapes of some mutations. 85 Future work should focus on microenvironment alterations in CMML, 86 because these modifications, which are mostly non-clonal, can represent an Achilles heel for cancer cells.
EPIGENETIC HETEROGENEITY
Epigenetic marks, including DNA methylation, histone posttranslational modifications, nucleosomal positioning and noncoding RNAs, are altered in cancer cells and contribute to oncogenesis. In CMML, a third of patients harbor aberrant hypermethylation of the TIF1g gene, which is involved in noncanonical TGF-b signaling and in transcription elongation, and haplo-insufficiency of Tif1g in mouse myeloid lineage generates a CMML-like neoplasm. 23 Though knowledge on the acquisition of epigenetic alterations is still beyond that of genetic lesions, it is likely that similar processes of clonal selection are at work with these aberrations. On the basis of this hypothesis, methylation marks have been used as molecular clocks in an attempt to trace the history of cancer clones. genes encoding components of the epigenetic machinery, including TET2 and ASXL1, are frequently mutated in CMML. 2 Even mutations in the JAK2 kinase could affect histone methylation. 88 In accordance with this model, a characteristic methylation pattern has been described in TET2-mutated CMML. 24 These aberrant epigenetic marks can be tracked to leukemic immature progenitors, suggesting that they do not simply reflect abnormal differentiation. 89 In the other, 'stochastic' model, epigenetic changes are randomly acquired, biological 'noise' playing the same role as genetic instability for genetic mutations. Epigenetic fluctuations leading to phenotypic diversification of otherwise clonal populations have indeed been observed in vitro, notably in hematopoietic cells during differentiation, 90 and in cancer cells. 91 In addition, there is evidence that epigenetic alterations accumulate with age, including in HSC. 92 Altogether, from an evolutionary perspective, epigenetic lesions could behave as genetic lesions during CMML initiation and progression.
ABNORMAL DIFFERENTIATION IN CMML: THE ROLE OF CLONAL HETEROGENEITY
CMML, together with other chronic myeloid malignancies, are characterized by a preserved although deregulated myeloid differentiation, with various phenotypic features related to dysplasia and proliferation of the granulomonocytic, erythroid and megakaryocytic lineages. Beyond the long-term clonal competition within the HSC compartment, a second layer of competition between normal cells and pathological subclones occurs during myeloid differentiation. Competition in the HSC compartment may rely on self-renewal potential, whereas competition in more mature compartments relies on proliferation potential and cytokine responsiveness ( Figure 5 ). This explains the distinct size of the mutated clone in the bulk of the tumor and in the HSC compartment. Mutations can be dominant in differentiated leukemic cells, yet only be present in a fraction of HSC. 25, 71 The differential competition between normal and mutated cells in the HSC versus differentiating compartments has been exemplified by MPN-associated JAK2 mutations, [93] [94] [95] which undergo massive expansion in differentiating cells, when homodimeric receptors such as granulocyte colony-stimulating factorG-CSF and EPO receptors become expressed. 92 The mechanism driving TET2-mutated cell expansion with differentiation is less clear, but TET2 mutations could promote the expansion of JAK2-mutated clones during erythroid differentiation. 95 The genetic characteristics of leukemic cells can shape the phenotype of chronic myeloid neoplasms.
First, a direct link can exist between the function of a mutated gene and the phenotype, for example, mutations in SF3B1 gene cause erythroid dysplasia with ringed sideroblasts, a phenotype that emerges at a late stage of differentiation. The percentage of ringed sideroblasts simply mirrors the size of the SF3B1-mutated clone in erythroid precursors. 19, 96 Second, the copy number of the mutation can drive the phenotype, for example, erythrocytosis correlates with the expansion of homozygous JAK2 V617F -mutated subclones, 93 with increased sensitivity to EPO of homozygous subclones explaining their ability to outcompete other clones during myeloid differentiation. [93] [94] [95] Additional mechanisms may account for the rare cases of minor and stable JAK2 V617F homozygous subclones in essential thrombocytemia. 93, 97 Third, the disease phenotype could depend on the level of clonal dominance in the hematopietic cell hierarchy. In particular, early dominance of TET2 in the CD34 þ /CD38 -compartment, but not late dominance (in the CD34 þ /CD38 þ compartment and below), could lead to the specific monocytosis of CMML (Figure 3) . 25 MDS or atypical MDS/MPN could evolve into CMML through the extension of mutated TET2 dominance in the very early phases of hematopoiesis. Importantly, the finding that the characteristic phenotype of CMML emerges at an earlier stage than JAK2 and SF3B1 phenotypes is concordant with the clonal expansion at the level of the most immature CD34 þ /CD38 À cells. 25 Fourth, the granulomonocytic hyperplasia that is characteristic of CMML has long been thought to result from hypersensitivity to GM-CSF, which is actually restricted to the B35% of patients harboring mutations affecting signaling genes (N/KRAS, CBL, JAK2). 98 In many cases, these mutations are acquired during the course of the disease, 25, 99 indicating that another mechanism may account for the granulomonocytic expansion. Granulomacrophagic progenitors are quantitatively and qualitatively normal, but multipotent progenitors and common myeloid progenitors are expanded, 25 as in MDS, 89 and these progenitors are skewed towards granulomonocytic differentiation at the expense of the erythroid lineage.
Such differentiation skewing, which had been suspected also in PMF 27,100 could involve biased lineage decision or lineage amplification. Solving this issue will require the use of single-cell tracking experiments. 101, 102 If our model holds true, the rare patients with benign TET2-mutated clonal hematopoiesis 54 are expected to result from late clonal amplification, after lineage commitment. The level of clonal expansion of TET2-mutated clones in immature versus mature progenitor compartments might depend on the presence of additional mutations, and on the self-renewal capacity of the HSC origin. 34 Lineage skewing could be affected by the self-renewal potential of HSC, by the cellular microenvironment, 103 and by paracrine loops between differentiated stem cells. 104 How these lineage-biased HSC subsets contribute to leukemogenesis remains an exciting avenue for future research. 37 In the absence of TET2 mutations, the granulomonocytic skewing of immature progenitors that characterizes CMML may be caused by other oncogenes, for example, a marked differentiation bias was noticed in ASXL1-mutated cases (Itzykson et al. unpublished observations), and a similar differentiation bias could be induced by rare translocations involving the RET oncogene. 105 
JMML SPECIFICITIES
Three main characteristics separate JMML, which is a rare and aggressive myeloid malignancy of infants or young children, from CMML, which is basically a disease of aging. 106, 107 First, hypersensitivity of myeloid progenitor cells to GM-CSF in colony forming assays (CFU-GM) is one of the hallmarks of JMML, while being limited to a fraction of CMML, mainly those with mutations that affect cell signaling components. Second, a molecular alteration of the RAS signaling pathway, which is often unique in the whole exome, and sometimes appears on a background of specific congenital syndrome such as neurofibromatosis or Noonan syndrome, is identified in 85-90% of JMML patients. Conversely, mutations affecting epigenetic, splice or transcription factor genes are very rare in JMML. Last, allogeneic stem cell transplantation is usually the best therapeutic option to propose to these young patients, even though some children with RAS or CBL mutations may experience spontaneous resolution.
AML PROGRESSION
Twenty to 30% of CMML cases eventually transform to AML. The rare CMML cases harboring DNTM3A 108 and NPM1 mutations resemble 'smoldering' acute leukemias. 25 In the other cases, the mechanisms of transformation to AML remain unknown. The dominant view is that transformation arises from the massive expansion of a clone with novel, highly fit, genetic lesions, thereby increasing clonal heterogeneity, as described in transformed MDS. 12 On the basis of observations made in JAK2-mutated
SPOTLIGHT
Evolution and CMML clone architecture R Itzykson and E Solary MPN, the dominant clone at transformation may arise from a minor subclone of the chronic phase of disease. 109 The nature of genetic lesions involved, and the role of microenvironment changes in the transformation are a matter of future research. A natural evolution of high-fit clones, for instance those with ASXL1 mutations, leading to AML without any novel genetic lesion cannot be excluded. Both mechanisms likely contribute to progression, explaining the inflection point in the cumulative incidence of AML transformation in CMML ( Figure 6 ). 25, 111 PROGNOSTIC IMPACT OF MOLECULAR ALTERATIONS Several prognostic scores have been proposed in CMML, using diverse combinations of clinical, biological and cytogenetic features, but none gained widespread acceptance for various reasons. A very recently described CMML-specific prognostic scoring system included FAB and WHO subtypes, cytogenetic, and red blood cell transfusion dependency, with or without lacticodeshydrogenase level. 112 By integrating molecular lesions with clinical variables, we also proposed an efficient score that, for the first time, includes a molecular parameter, that is, mutations in ASXL1 gene. Among all the genes that can be mutated in CMML, ASXL1 is the only one whose mutation has a negative prognostic impact on AML-free and overall survival in multivariate analyses. The proposed score attributes 3 points for WBC 415 Â 10 9 /l, and 2 points for four age465 years, anemia, platelet count o100 Â 10 9 /l and ASXL1 status, respectively. This score allows categorizing patients into low (0-4 points), intermediate (5-7 points; 34%) and high (8-12 points; 24%) risk groups, with median overall survival not reached, 38 and 14 months, respectively. 113 
THERAPEUTIC CONSEQUENCES OF MOLECULAR ANALYSES IN CMML
The search for molecular alterations can be used first to refine the diagnosis in patients with monocytosis. BCR-ABL rearrangement that identifies chronic myeloid leukemia must be systematically explored, a mutation in KIT gene that characterizes systemic mastocytosis is searched when mast cells infiltrate the skin or the bone marrow, and fusion genes involving PDGFR (platelet-derived growth factor receptor, a or b) of FGFR1 (fibroblast growth factor receptor 1) genes have to be explored when an eosinophilia is associated to monocytosis. In these three situations, refining the diagnosis will lead to the therapeutic use of a tyrosine kinase inhibitor.
Otherwise, the treatment of CMML is not fully codified. Allogeneic stem cell transplantation, which is currently the only curative option, is deferred in most cases because of patients age and unclear prognosis. 113 The frequent relapses suggest the presence of subclones escaping the immune effects of allogeneic graft. Non curative options mainly include cytoreductive chemotherapy like hydroxyurea to mitigate myeloproliferation, erythropoieisis-stimulating agents to cope with anemia, and hypomethylating agents that can do both. Cell genotyping and next-generation sequencing confirmed that none of these therapeutic approaches can eradicate the clone. 25 These therapies sometimes select minor subclones, for example, we observed the selection of an NRAS-mutated subclone upon hydroxyurea. We noticed also that recombinant erythropoietin could increase the proportion of wild-type CD34 þ /CD38 À cells through still hypothetic mechanisms. 25 Owing to the limited number of clinical trials specifically dedicated to CMML and the clonal heterogeneity of the disease, the mutations or epigenetic changes that affect the therapeutic response are still poorly identified. In a phase II clinical trial, testing the efficacy of the demethylating agent decitabine in a small cohort of patients with an aggressive form of the disease, TIF1g promoter methylation did not predict decitabine efficacy. 114 Nevertheless, the re-expression of TIF1g gene in peripheral blood monocytes could be used as a biomarker of decitabine efficacy. 25 Interestingly also, the response rate was higher in patients with TET2 mutations, without reaching significance in this small size phase II trial. Ongoing studies will indicate if TET2 mutations (when they are not associated with a mutation in ASXL1), are predictors of a better response to demethylating agents, as described in MDS, and whether a specific pattern of DNA methylation will predict hypomethylating agent efficacy.
Tailoring new rational therapies aiming at eradicating the pathological clone is the ultimate goal, allowing residual normal HSC to expand. As suggested above, assessing the clonal status of HSC, which is distinct from that of differentiated cells, will be essential to design and evaluate these new therapeutic strategies, and iterative snapshots of clonal architecture in the early phase of therapy may allow extrapolating long-term clonal evolution and adapting the therapeutic approach. Indeed, a treatment that will correct the proliferative advantage of a subclone during differentiation will not necessarily alter its fitness in the stem cell compartment.
Ideally, identification of an oncogenic event, to which the leukemia-initiating cells are addicted is needed. This event will be an oncoprotein that will need to be degraded or inhibited, or a loss-of-function that will be targeted indirectly if synthetic lethality can be triggered. Major sources of resistance can be anticipated if such a targeted therapy is used alone, including the induction or selection of minor subclones with sometimes normal or even detrimental fitness before therapy. 77 Therefore, a non-specific cytoreduction will probably be needed first in an attempt to eliminate these minor subclones before the onset of the targeted therapy. 77, 115 Alternating strategies would be to seek 'limited' clonal eradication, allowing the persistence of clonal benign hematopoiesis, 54 or restore normal differentiation without clonal eradication, as obtained with MEK inhibitors 116 and hypomethylating agents. 25, 89, 117, 118 The combination of drugs selecting opposite phenotypes, with alternative rather than concomitant administration to generate a vicious circle of futile adaptation, could also mitigate the disease progression. Figure 6 . Cumulative incidence of AML transformation in CMML: observed cumulative incidence of WHO-defined AML transformation in the Groupe Francophone des Myelodysplasies cohort of 312 CMML patients, 110 considering death as a competing risk. Two mechanisms could possibly promote acute blastic transformation: the first (green line) would be the rapid expansion of existing clones, for example, when ASXL1 gene is mutated, whereas the second (red line) would be the later occurrence of additional genetic events, for example, mutations in NPM1 or in DNMT3A.
CONCLUSION
The genetic heterogeneity of CMML, both in each patient and between patients, indicates that the disease can be generated through a wide array of evolutionary trajectories. Current approaches suggest that a preferred order of mutation accumulation is TET2 (or IDH1 and IDH2) or ASXL1 first, SRSF2 or an alternative splice gene second, then, in 35-40% of cases, a signaling gene mutation inducing GM-CSF hypersensitivity and myeloproliferation. The respective frequency of each gene mutation could possibly bias this evaluation. Nevertheless, early clonal dominance, linear accumulation of mutations with limited branching, and competitive advantage to the more mutated cells during differentiation are the main characteristics of the CMML clonal architecture. Exploiting the evolutionary dynamics of clonal heterogeneity to treat cancer is certainly a daunting task. After all, modern antiretroviral combinations allow control, rather than eradication of HIV, a virus counting only nine proteins.
